New Survey Results Show That Few Young Women Smokers Able to Quit; Nymox Pharmaceutical Corporation's NicAlert Product Offers a New Tool for Smoking Cessation Programs
MAYWOOD, N.J.--(BUSINESS WIRE)--July 24, 2003--The results of two surveys released by the American Legacy Foundation show that 65% of young women smokers want to quit but only 3% succeed. The American Legacy Foundation, an independent public health founda
"These results make it clear that quitting smoking is very difficult, regardless who the smoker is," said Dr. Michael Munzar, Medical Director of Nymox Pharmaceutical Corporation NYMX. "Effective smoking cessation programs are an essential part of any tobacco control program aimed at curbing the tragic toll and rising healthcare costs levied by cigarettes and other tobacco products. We believe that our NicAlert(TM) product can be a valuable aid to any smoking cessation program by providing a quick, easy, point-of-care method of monitoring and verifying smoking cessation efforts. NicAlert(TM) can help customize therapy for quitting smoking."
NicAlert(TM) is a powerful one-step urine test for determining smoking and tobacco product exposure and use. NicAlert(TM) received clearance for medical use from the U.S. FDA in October 2002. NicAlert(TM) provides the capability of measuring cotinine levels in an easy-to-use, cost effective, rapid format. The NicAlert product does not require any instruments or special training for its use.
NicAlert(TM) can help smokers quit as shown by the results of a large European clinical trial which found significant smoking reduction over the four-month trial period when nicotine replacement therapy (NRT) was combined with individual cotinine levels as measured by NicAlert. The study of NRT with NicAlert(TM) was undertaken at the Hirslanden Lung Center Zurich, Switzerland. The lead investigator was Dr. Karl Klingler. Some results from this study were presented at the 75th anniversary of the Congress of Swiss Pneumologists in St. Gallen, Switzerland. Further results will be presented at the 12th World Conference on Tobacco or Health in Helsinki August 3-8, 2003.
NicAlert(TM) is being used as the official test agent in several smoking cessation programs to be offered by the American Respiratory Alliance. NicAlert(TM) has also been successfully used in quit- smoking contests sponsored by public health officials in Switzerland and Canada.
Two recent independent peer-reviewed studies found the technology employed in NicAlert(TM) to be an accurate, rapid and cost-effective means of confirming smoking status. One study, "Validating a Dipstick Method for Detecting Recent Smoking," Cancer Epidemiology, Biomarkers & Prevention (2002; 11: 1123-1125) examined the smoking status of patients at a cancer clinic and found that the results obtained using Nymox's tobacco product exposure test had an "excellent agreement" with state-of-the-art sophisticated laboratory measurements but at a substantially lower cost (over 90% less). The second study, "The Accuracy of Self-Reported Smoking Status Assessed by Cotinine Test Strips," Nicotine & Tobacco Research (2002; 4: 305-9) found Nymox's product to be "an inexpensive and rapid method to routinely biochemically confirm smoking status at a clinical visit." The authors described the Nymox product as a "simple, inexpensive and rapid measure to immediately confirm smoking status in field settings."
The U.S. Surgeon General, the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and many other public health organizations have targeted tobacco use as the single most preventable cause of premature death today. The CDC estimates that smoking causes over 440,000 premature deaths annually in the United States and creates an economic loss of over $150 billion a year.
More information about Nymox is available at www.nymox.com, email: firstname.lastname@example.org, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.